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Thereafter the patient attended clinic regularly. Over the next 2
years, blood pressure increased, eventually averaging 170/102 mm Hg;
the GFR declined by 1.70 mllmin/month. Antihypertensive treatment
was instituted, and over the following 7 years, the blood pressure
averaged 142/90 mm Hg; GFR continued to decline in a linear fashion,
the rate of reduction being 0.42 mI/mm/month.
Patient 2. A young man with insulin-dependent diabetes mellitus
since the age of 10 years was admitted to the clinic at the age of 23. He
had been treated for 6 years with conventional insulin therapy (NPH
insulin administered twice daily) and a controlled diet. Fasting plasma
glucose averaged 112 mgldl. He had early retinopathy and mild
neuropathy with increased vibration threshold values. Blood pressure
increased at the end of this pre-intervention phase, eventually reaching
130/103 mm Hg. The UAE increased at an average yearly rate of 28%,
from a value of 22 g/min at baseline to a value of 149 g/min during the
sixth year of followup. The GFR was well preserved throughout this
6-year period (154 to 142 mllmin). Urine sediment was normal and urine
culture was sterile. Following institution of antihypertensive treatment
________________________________________________________
at the age of 29, blood pressure averaged 122/88 mm Hg during the next
3 years of followup. The UAE subsequently decreased at an average
yearly rate of 21%, reaching a value of 43 g/min by the third year of
treatment. The GFR remained stable at 144 mI/mm.
Case presentations
Discussion
Patient I. A 30-year-old man was admitted to the Aarhus Kom-
munehospital because of uncontrolled diabetes mellitus, which had
been diagnosed 12 years earlier and had been treated with insulin and a
controlled diet ever since. The blood pressure was 130/90 mm Hg. Mild
retinopathy with a few microaneurysms, small hemorrhages, and one
soft exudate were noted. Laboratory studies following regulation of the
patient's diabetes revealed urinary albumin excretion (UAE), 15 4
g/min (mean SD; normal value, 5.1 1.0 g/min); glomerular
filtration rate (GFR) (by labeled iothalamate clearance), 152 mI/mm; and
renal plasma flow (RPF) (by labeled hippuran clearance), 710 mI/mm.
Blood glucose values during these investigations averaged 133 mg/dl.
Urine sediment was normal and urine culture was sterile.
After discharge, the patient did not attend the outpatient clinic for
followup. He was hospitalized again because of poor control of his
diabetes 3 years after the initial admission. He had been working hard
physically on an erratic schedule and was not adhering to the recom-
mended therapeutic regimen; he had reduced the amount of insulin he
was taking (lente insulin administered twice daily) from 84 to 40 units
per day and had not been following dietary advice. Blood pressure was
160/95 mm Hg. Vibration threshold measured at the right great toe had
increased from 23 volts during initial evaluation to 47 volts at followup
(normal value, <15 volts). Laboratory data included: UAE, 1573 28
sg/min; GFR, 105 mI/mm; RPF, 536 mI/mm. Urine sediment was
normal and urine culture was sterile.
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DR. CARL ERIK MOGENSEN (Professor of Medicine, Second
University Clinic of Internal Medicine, Aarhus Kommunehos-
pita!, Aarhus, Denmark): Early morphologic lesions of diabetic
nephropathy, such as glomerular basement membrane thicken-
ing and mesangial expansion, develop in practically all insulin-
dependent diabetics within a few years after the onset of their
metabolic abnormality [1]. Nonetheless, clinical diabetic ne-
phropathy with proteinuria, hypertension, and a decline in renal
function develops eventually in only about 45% of insulin-
dependent diabetics, the remainder being spared clinically
important renal disease [2—4]. Several benefits could be derived
from knowing early in the course of diabetes whether a patient
is likely to develop clinical diabetic nephropathy. First, such
information would have obvious prognostic implications. Sec-
ond, this knowledge, coupled with serial investigations of
systemic and renal hemodynamics, might shed light on the
pathogenetic mechanisms leading to the development of overt
diabetic nephropathy. Third, the existence of such a marker
would allow selection of patients for trials aimed at retarding
progression to renal failure. Such trials might include intensified
insulin treatment, low-protein diets, and early and aggressive
antihypertensive treatment. In this discussion, I will make the
case that "subclinical proteinuria" qualifies as such a marker or
predictive instrument.
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Proteinuria is the laboratory hallmark of diabetic nephrop-
athy and is highly predictive of uremia and early mortality [5,
6]. Until recently, most diabetes clinics have employed exclu-
sively the Albustix test or similarly crude dipstick methods in
screening patients for proteinuria. However, such methods give
a positive result only when urine albumin concentration (and
excretion) is increased from normal by a factor of approxi-
mately 20. Recent studies using more sensitive techniques have
revealed the existence of early abnormalities in protein excre-
tion, termed either "subclinical proteinuria" or "microalbumin-
uria." These studies have documented that even a slight
elevation of urine albumin excretion—far below the level found
in Albustix-positive "clinical proteinuria"—is a strong predic-
tor of future overt diabetic nephropathy. Diabetic patients
devoid of microalbuminuria have only a small risk of developing
clinical proteinuria over the next 10 to 14 years; therefore, the
excess mortality of such patients in comparison with the
nondiabetic population is likely to be small [6]. Because I
believe that detection of microalbuminuria is currently the best
way to identify early in the course of the disease patients at risk
of developing clinical diabetic nephropathy, I would like to
pause for a moment to cite some of the recent work appearing
on albumin measurement in diabetes and other disorders.
The past 5 years have witnessed extensive clinical investiga-
tion into the area of albumin as a marker in detecting, treating,
and prognosticating disease. Individuals who wish to pursue
these studies might find valuable papers relating to studies on
the development of sensitive laboratory techniques for detect-
ing albumin, such as radioimmunoassay and other immunoas-
say screening procedures [7—251; methodologic investigations
[26—33]; and pathophysiologic studies [34-44]. Also, studies in
diabetics have appeared relating to albumin excretion during
exercise [45—56] and in association with changes in blood
pressure [57—60]. Metabolic control as well as intensified treat-
ment have received attention [26, 61—69], and the l980s have
brought studies on associated microvascular diabetic lesions,
especially retinopathy [70—74]. The structural correlate in the
kidney to microalbuminuria is still not fully elucidated [75—781.
The use of albuminuria to predict diabetic nephropathy and to
determine its progression have been studied in several centers
in Europe [79—84]. Epidemiologic studies of microalbuminuria
have appeared [85—88], including clinic-based surveys [89—94]
and studies of specific populations such as children [95—105];
young adults [26, 106]; elderly, primarily non-insulin-dependent
patients [107, 108]; and newly diagnosed patients [26, 107].
Reports also are appearing on new methods of intervention
[65—69, 109—112], but this work is just beginning. Many surveys
have summarized work on microalbuminuria [113—128]. Finally,
microalbuminuria has been evaluated in diabetic rats [129].
Clinical research also has proceeded in non-diabetic patients,
specifically those with hypertension [130-133], pre-eclampsia
[134], and other generalized disorders [135—139]. My colleagues
and I have investigated the urinary excretion of albumin in
patients taking a variety of drugs [140—145] and hormones
[146—152] and have studied the effect of glucose, amino acids,
and other metabolic agents [40, 153, 154]. Protein-rich meals
have no effect on albumin excretion [154]. Monitoring of early
renal changes after exposure to nephrotoxic agents seems to ne
an important new area for investigation [155, 156].
General definition of microalbuminuria
The term microalbuminuria was coined in 1982 at Guy's
Hospital in London 1106]. The same group developed the first
radioimmunoassay for detecting albumin in low concentrations
in the urine in 1963 [7]. Many laboratory techniques, based on
radioimmunoassay or chemicoimmunoassay, currently are
available for determining urine albumin levels [8—22]. Microal-
buminuria is defined as abnormally elevated UAE in the ab-
sence of clinical proteinuria (as measured by standard labora-
tory methods).
In one study, the UAE measured in 24-hour samples in 23
normal men and 20 normal women (age 22—40 years) averaged
4.7 4.7 g/min (SD) (range, 2.6—12.6) and 4.3 4.8 (range,
1.1—21.9), respectively [128]. The day-to-day variation in UAE
of 24 normal subjects, estimated as the coefficient of variance of
three 24-hour samples, was 3 1.3% [128]. The mean UAE at rest
(short-term collections over several hours, n 18, all males)
was similar (4.8 1.4 p.glmin), but with a somewhat narrower
range (2.3—8.3 gImin). Higher values for UAE were recorded
in some elderly individuals in a population study [88].
Because the UAE varies with posture [26] and with exercise
[45—56, 128], evaluation should be carried out only on urine
collected under standardized conditions. Each of the following
procedures is considered acceptable: (1) short-term collections
over one or several hours in the laboratory or clinic; (2)
overnight (approximately 8-hour) urine collection; (3) a 24-hour
collection; (4) an early morning urine sample corrected for urine
flow by creatinine measurement (mainly for screening pur-
poses) [26, 33, 94]. I will discuss the utility of these various
procedures in the next section. Because the coefficient of
variance in UAE is approximately 45%, at least 3 urine collec-
tions are necessary [26, 29, 60].
In addition to laboratory techniques for quantitative determi-
nation of urine albumin levels, newly developed screening
procedures based on immunoreaction [23] or on the protein
error for pH indicators are available [24, 25]. The Microal-
butest, a tablet method, is positive at a urine albumin concen-
tration of approximately 40 g/ml [24, 25], in contrast to the
Albustix test, which is positive at a concentration of approxi-
mately 140 LgIml. The Microalbutest can be used as a "bed-
side" examination for microalbuminuria [24], but quantitative
methods should be employed whenever possible.
Predicting diabetic nephropathy and its progression
Studies from three centers show that the appearance of
microalbuminuria predicts clinical diabetic nephropathy in in-
sulindependent patients. The discrimination level of UAE, that
is, the level of UAE which, if exceeded, predicts the develop-
ment of clinical diabetic nephropathy, varies from center to
center. This variability is likely due to differences in urine
collecting procedures, differences in patient-sample composi-
tion, and differences in the duration of followup (Table 1).
We found the lowest discrimination level of UAE to be 15
pg/mm when urine samples were collected over several hours in
the laboratory or in the clinic and when the mean followup time
was 10 years [83]. We used three excretion rates on average
(Fig. I). A somewhat higher discrimination value (30 Wmin)
was found in a study employing overnight urine collections [81].
Finally, the highest discrimination value, 70 pg/mm, was found
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Londona Copenhagenb Aarhusc
Female/male 22/41 42/29 0/43
Followup (%) 75% 100% 98%
Mean age at screening 40 30 25
(years) (17—60) (13—50) (18—31)
Mean duration of diabetes 10 12 12
at screening (years) (1—41) (2—36) (7—20)
Followup period (years) 14 mean, 6 mean, 10
Proposed discrimination 30 g/min 70 g/min 15 .eg/min
value
Development of DN above 7/8 7/7 12/14
discrimination value
Development of DN below 2/55 3/64 0/29
discrimination value
Urine sample Overnight 24-hour Short-term at
hospital
Number of urine samples 1 3 3
Methods RIA Radial immune
diffusion
RIA
in a study using 24-hour urine collections [711. The differences
in the discrimination values among these studies suggest that,
when evaluating early nephropathy in insulin-dependent pa-
tients, one should obtain a baseline value with the patient in the
supine or sitting position, preferably under supervised condi-
tions. Nonetheless, as in Table 1, the differences in the discrim-
ination values in the three studies do not materially affect the
reliability of the test in predicting clinical diabetic nephropathy.
0 lOy 0 iCy
Fig. 2. Ten-year followup study showing development of clinical pro-
teinuria ()')and no clinical proteinuria (—') in patients with low or with
elevated urinary albumin excretion rates or concentrations. A few
patients developed microalbuminuria, Based on Refs. 82 and 83. Type
I is insulin-dependent patients and Type II non-insulin-dependent
patients.
Figure 2 summarizes our data on the predictive value of
microalbuminuria for the development of clinical proteinuria in
insulin- as well as non-insulin-dependent patients [82, 83]. The
data indicate that the risk of clinical nephropathy at 10 years of
followup is higher in young insulin-dependent patients with
microalbuminuria (about 80%) than in elderly patients with
microalbuminuria (about 22%). On the other hand, patients
without microalbuminuria, whether young or old, have only a
small risk of developing clinical proteinuria over the next
decade.
The rate of progression of proteinuria in the early phases of
diabetic renal disease has been incompletely evaluated [60, 69].
Evidence suggests that the rate of progression is slow, namely,
a mean rise in UAE of approximately 20% per year [60].
Therefore, the microalbuminuria phase, that is, the stage of
incipient diabetic nephropathy, is likely to last an average of
approximately 8 to 10 years. In some diabetic patients, how-
ever, UAE progresses more rapidly, as fast as a 60% increase in
albumin excretion per year, usually in association with poor
blood pressure control. Also, I suspect that proteinuria pro-
gresses more rapidly in poorly controlled diabetic patients, for
example, in noncompliant patients [3, 5], as in the first patient
presented here. , For obvious reasons, however, controlled
studies are difficult to carry out. In the case of extraordinarily
rapid progression of proteinuria, nondiabetic renal or systemic
disease should be suspected, but poor control of diabetes as
well as high blood pressure are also possibilities that should be
borne in mind.
We used multiple regression analysis in young male patients
with microalbuminuria to study the factors that influence (1) an
increase in UAE, (2) the rate of fall in GFR, and (3) develop-
ment of hypertension. The patients' age at diagnosis was less
than 20 years. The initial duration of illness was 3 to 20 years,
and the followup period was more than 7 years. We required the
UAE to be less than 70 iWmin at entry. The UAE, GFR, and
RPF were measured initially and at followup. All of the 31
Table 1. Summary of predictive studies of diabetic nephropathy (DN)
based on early microalbuminuria
Type I Type II
100
50
• 15
Co
>.
CoC
80%
Mean 20%
0%
Mean 100%
22%
ioo
Mean 78%C0
30
Mean
a From Ref. 71.
b From Ref. 81.
C From Ref. 83.
>600 I
Co
0.0
a0
0
U.
3 5 15 30 70 150 250
Initial albumin excretion (pg/mm)
Fig. 1. Followup urinary albumin excretion rate plotted against initial
albumin excretion rate in 43 male diabetics followed for 7 to 14 years
[mean, 10,4 3 (SD) years]. Mean age at diagnosis, 12 years; mean
duration of diabetes at initial examination, 13 years.
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InitiaV' At followup"
Age at diagnosis of 14 4.0 (5—20) 14 4.0 (5—20)
diabetes (years)
Systolic blood 124 8.9 (110—150) 127 12.2 (110—160)
pressure (mm Hg)
Diastolic blood 81 7.7 (65—95) 86 8.9 (70—105)
pressure (mm Hg)
Mean blood pressure 95 7.2 (82—1 13) 100 9.5 (87—123)
(mm Hg)
Plasma glucose 10 3.9 (4—18) 11 5.5 (4-21)
(mmol/liter)
GFR (,nlInzin) 140 12.4 (117—168) 126 25.0 (13—157)
RPF (mi/mips) 580 73 (446—746) 512 118.5 (75—772)
UAE (g/min) 11 8.6 (2.3—28.7) 253 673.2 (1 .2—2730)
patients fulifihing these criteria accepted reevaluation, which
took place at a mean of 11.5 years after the initial examination.
Two patients with diabetes for 3 years were excluded from the
study because in both instances an initially high UAE rapidly
returned to normal [59].
Clinical data and results of renal function tests in these 31
patients both at entry and at followup are shown in Table 2. We
examined the relative roles of all parameters from the initial
evaluation (listed in Table 2) in determining the change in UAE
(log-transformed), GFR, and mean blood pressure. Initial high
UAE and initial high GFR appeared to be the major correlates
of followup UAE. With respect to the rate of fall in GFR, if
initial GFR was included in the analysis, the initial GFR was
shown to be the dominant factor; interestingly, the higher the
initial GFR, the poorer the late prognosis. If initial GFR was
excluded, however, the initial UAE was the only determinant,
without any significant contribution from other variables. Fi-
nally, initial high UAE was the major determinant of subse-
quent elevated mean blood pressure.
Although microalbuminuric patients who progress to overt
diabetic nephropathy as a group tend to have higher initial
blood pressure levels than do those who do not progress (Figs.
3A, 3B), the predictive power of elevated blood pressure is
much less pronounced in comparison to early increases in UAE
and GFR. Indeed, our analysis revealed that the latter two
parameters are the most powerful factors with respect to
predicting progression to overt diabetic nephropathy, whether
focusing on final TJAE or on the rate of fall in GFR.
The observation that an elevation of UAE, an increase in
glomerular filtration, and an early rise in blood pressure coexist
in incipient diabetic nephropathy might prove to be extremely
important from the therapeutic standpoint.
Redefinition of diabetic nephropalhy
The observation that microalbuminuria is a predictor of
subsequent clinical diabetic nephropathy and the recent de-
scription of an early hyperfunction-hypertrophy stage of this
disease [1191 underline the need for redefinition of diabetic
nephropathy. We have proposed a new scheme that encom-
Initial Followup Initial Followup
Fig.3. A Systolic and diastolic blood pressures in young, male, insulin-
dependent diabetics not showing progression in UAE. Difference from
controls (115 9.8/73 8.0, n = 18), *2 p < 2.5%, ***2p < 0.01%. B
Systolic and diastolic blood pressures in young, male, insulin-depen-
dent diabetics showing progression in UAE. For both Figs. 3A and 3B,
mean age at diagnosis, 12 years; diabetes duration at initial evaluation,
13 years; mean followup, 10.4 years. Difference from controls (115
9.8/73 8.0, n = 18), **2p < 0.1%, ***2p < 0.01%.
passes various developmental stages of diabetic nephropathy
[1191. These stages as well as their main characteristics are
outlined in Table 3. Stage 1, present at the time of diagnosis of
insulin-dependent diabetes, is characterized by glomerular
hyperfunction and hypertrophy. Certain features of this stage
also can accompany diabetes of longer duration, when meta-
bolic control is imperfect. Stage II, the "silent" stage, is
characterized by the development of renal lesions (predomi-
nantly in the glomerulus), but albumin excretion is normal.
Stage III, incipient diabetic nephropathy, is characterized by
microalbuminuria, and causes a high risk of development of
overt diabetic nephropathy. I will elaborate on this stage in a
moment. Stage IV, overt (clinical) diabetic nephropathy, is
characterized by proteinuria, hypertension, and a subsequent
fall in GFR. Stage V corresponds to end-stage renal failure with
uremia.
Table 2. Clinical and renal function data in patients with incipient
diabetic nephropathya
a Multiple regression analysis was used to identify the correlates of
follow-up UAE, rate of fall in GFR, and elevated blood pressure.b Mean SD and ranges shown (n = 31).
Log-transformed in calculations.
80*
Systolic pressure Diastolic pressure
mm Hg
100
90
80
70
60
Initial Followup Initial Followup
Systolic pressure Diastolic oressure
A
mm Hg
140
130
120
110
100
B
mmHg
180
160
140
120
100
2p = 3%
mrnHg
149*** 120
100
80
/
n.s 2p = 3.7%
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Table 3. Stages in diabetic nephropathy (DN)
Suggested
Stage Designation
Main
characteristics
Main structural
changes GFR (mi/mm)
Albumin
excretion
(UAE)
Blood
pressure
main
pathophysio-
logic change
Stage I Hyperfunction and
hypertrophy
stagea
Large kidneys
and
glomerular
hyperfiltration
Glomerular
hypertrophy;
normal base-
ment mem-
brane and
mesangium
150 May be
increased
N (May fall
initially
during
insulin
treatment)
Glomerular
volume
expansion
and
increased
intraglo-
merular
pressure
Stage II
In short-term Normal UAE Increasing basal With or without N (Often N Changes as
diabetes membrane hyperfiltratio&' increased indicated
(2—15 (bm) in stress above but
years)
"Silent" stage
with normal
UAE but
structural lesion
present
thickness and
mesangial
expansion
situations) quite
variable
(dependent
on
metabolic
control?)
In long-term No or few With or without N (Often N or slightly In addition
diabetes studies hyperfiltrationb increased
in stress
situations)
elevated increased
synthesis
of bm and
bm-like-
material
Stage III Often elevated Glomerular
Early
Late
Incipient DN Persistently
elevated
UAE
Severity
probably in
between II
and IV
=l60
l3O
20—70
/.Lg/min
70-200
1min
compared to
healthy
subjects;
also blood
pressure
elevated
during
exercise
closure
probably
starts in
this stage
In some
patients
high intra-
glomerular
pressure
Stage IV
Early Clinical
proteinuria
or UAE
>200
igImin
<200
Increasing rate
of glomerular
closure
130—70 >200 eg/min Often frank
hypertension
High rate of
glomerular
closure
and
advancing
mesangial
Intermediate Overt DN Lg/min
<200
g/min
Hypertrophy of
remaining
glomeruli (as
70—30 Hypertension
almost
ubiquitous
expansion
Advanced in III) 30—10 Hypertension
almost
ubiquitous
Hyperfiltra-
tion in
remaining
glomeruli
(deleterious)
Stage V Uremia End-stage
renal failure
Generalized
glomerular
closure
0—10 Decreasing High but often
controlled
by dialysis
treatment
Advanced
lesions
and
glomerular
closure
a Changes present probably in all stages when control imperfect.b Marker of future nephropathy (if GFR > 150 mI/mm).
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Microalbuminuria and incipient diabetic nephropathy
I am using recently accepted definitions in assessing patients
with early diabetic nephropathy [157]. Microalbuminuria is
considered present when the UAE is greater than 20 g/min and
less than or equal to 200 p.g!min. This level of UAE corresponds
to approximately 30 to 300 mg per 24 hours. Incipient diabetic
nephropathy (Stage III) is considered present when microalbu-
minuria is found in 2 of 3 urine samples collected consecutively,
preferably within a period of 6 months. If more than 3 samples
are available, the mean UAE should lie within the microalbu-
minuric range of 20 to 200 g/min. Urine should be sterile and
obtained in the non-ketotic state. The best possible control of
diabetes should be achieved prior to determining the UAE.
Other causes of increased UAE should be excluded, especially
if diabetes has been present for less than 6 years. Overt diabetic
nephropathy (Stage IV) is considered present when the UAE is
greater than 200 .tg/min in at least 2 of 3 urine samples collected
within 1 to 6 months, or when the mean value of the UAE of
multiple collections exceeds 200 j.g/min. As is the case for
incipient diabetic nephropathy, urine samples should be sterile
and obtained in the non-ketotic state; other causes of increased
UAE should be excluded. According to these definitions, the
dipstick test for urine protein should not be applied when
classifying diabetic renal disease.
Several abnormalities have been documented in patients with
persistent microalbuminuria, that is, incipient diabetic nephrop-
athy (Stage III):
(1) During the early stages of incipient diabetic nephropathy
(UAE of 20 to 70 tgImin), the GFR can be elevated above
2705.1 -4-.
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Fig. 4. A UAE in the various stages of diabetic nephropathy. C, controls; D11, stage of normal urinary albumin excretion rate; D111, incipient
diabetic nephropathy; D1, overt diabetic nephropathy. B GFR in the various stages of diabetic nephropathy. Abbreviations are as in Fig. 4A. C
RPF in the various stages of diabetic nephropathy. Abbreviations are as in Fig. 4A. D Systolic blood pressures in the various stages of diabetic
nephropathy. Abbreviations are as in Fig. 4A. E Diastolic blood pressures in the various stages of diabetic nephropathy. Abbreviations are as in
Fig. 4A.
Initial funduscopy
Fig. 5. Followup funduscopy plotted against initial funduscopy in
patients with insulin-dependent diabetes (10.4 year followup), with and
without initial microalbuminuria. •, Initial UAE <15 g/min or no
progression in elevated albumin excretion (2 patients with albumin
excretion rate at 15.9 and 23.3 g/min did not have increased albumin
excretion at followup). U, Initial UAE 15 gImin and increasing
albumin excretion.
normal. This hyperfiltration is not accompanied by correspond-
ing changes in RPF. As microalbuminuria progresses, GFR
returns to the normal range [83]. Finally, patients who enter the
stage of clinical proteinuria exhibit gradual decreases in GFR
and RPF. Figures 4A, 4B, and 4C depict changes in UAE, GFR,
and RPF in the various stages of diabetic nephropathy.
(2) Several studies have recognized that elevated blood
pressure is an early accompaniment of incipient diabetic
nephropathy; the magnitude of the elevation is in the range of
10% to 15% above values in control subjects [57—60, 71, 83]. In
a recent study of microalbuminuric patients, mean arterial
blood pressure increased by a mean of 4.5 mm Hg during 2
years of followup [69]. Figures 4D and 4E depict changes in
systolic and diastolic blood pressure in the various stages of
diabetic nephropathy.
(3) Diabetic retinopathy is more advanced in patients with
microalbuminuria than in patients with silent, Stage II disease
[72]. Importantly, patients at risk of proliferative diabetic
retinopathy can be identified on the basis of microalbuminuria
[73, 74] (Fig. 5).
(4) Transcapillary escape rate of albumin is increased in
incipient diabetic nephropathy [69].
Pat hogenesis and morphologic correlates of incipient diabetic
nephropathy
On the basis of these and other observations, it is likely that
a combination of hemodynamic [120, 125, 158—160] and bio-
1 10 100 1.000 10.000
Albumin excretion rate (g/min)
Fig. 6. Beta-2-microglobulin excretion plotted against urinary albumin
excretion rate in the various stages of diabetic nephropathy. D11,
patients with normal urinary albumin excretion rate; D111, incipient
diabetic nephropathy; D1, overt diabetic nephropathy.
chemical changes [161, 162] characteristically found in diabetic
patients given standard insulin therapy are responsible for the
pathogenesis of microalbuminuria and diabetic nephropathy. It
is possible that the mechanisms responsible for the transient
microalbuminuria associated with the poor metabolic control
characteristically seen at the time of first presentation (rapidly
reversible microalbuminuria) [26, 61] are different from those
leading to persistent microalbuminuria and incipient diabetic
nephropathy, typically seen after 7 to 15 years of diabetes. I
believe, however, that both transient and persistent microalbu-
minuria have some pathogenetic mechanisms in common. Ac-
cording to my hypothesis, glomerular hypertension is involved
both in transient microalbuminuria and hyperfiltration and in
the long-term disruption of the structural integrity of glomeruli.
In addition, the altered metabolism of the diabetic state proba-
bly produces increased basement membrane thickening and
mesangial expansion, as well as changes in the structural and
functional characteristics of the basement membrane. I further
believe that the structural changes are at least partially inde-
pendent of the changes in intraglomerular blood pressure [1, 75,
127]. That the persistent microalbuminuria of incipient diabetic
nephropathy is of glomerular origin has been well documented
(Fig. 6); the excretion of beta-2—microglobulin, a marker of
tubular damage, does not increase until UAE rises to approxi-
mately 1000 p.g!min.
In all probability, systemic blood pressure rises only when
structural glomerular changes become prominent. Even a slight
elevation in blood pressure appears to be an accelerating factor
in the course of diabetic nephropathy [59, 69]. In fact, blood
pressure generally is normal in diabetics with minor degrees of
microalbuminuria but tends to be elevated in diabetics with
more pronounced microalbuminuria [58, 83]. The coexistence
of increased systemic blood pressure, diabetic retinopathy [72],
and an enhanced transcapillary escape rate of albumin [69, 70]
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Table 4. Causes of microalbuminuria in insulin-dependent diabetes
Causes
Approximate level of albumin excretion ratea
(g/min)
Newly diagnosed 5—60
diabetes
Poor metabolic 5—6O
regulation
Physical exercise 5—60
Essential 5—20
hypertension in
diabetes (seldom)
Urinary tract Moderate increase
infection
Non-diabetic renal or Variable
systemic disease
Early phases of 20—200
diabetic
nephropathy
(incipient
nephropathy
a Baseline values, except for physical exercise
in patients with incipient diabetic nephropathy argues for the
existence of generalized vascular disease early in the course of
diabetes. This view is supported by the finding of excess
mortality even in microalbuminuric patients with non-insulin-
dependent diabetes [82, 84].
Only a few studies have examined the structural correlates of
incipient diabetic nephropathy. Evidence suggests that the
morphologic changes are similar to those occurring in overt
diabetic nephropathy but are less pronounced [751. However,
the histologic findings of patients with incipient diabetic
nephropathy have not been compared systematically with those
of a comparable group of diabetic patients who do not have
persistent microalbuminuria.
In a cross-sectional study of patients with variable degrees of
diabetic renal involvement, Mauer et al found an association
between the percentage of fibrotic glomeruli and the level of
microalbuminuria [76]. Fibrotic or occluded glomeruli are not
likely to leak proteins into the urine, but the number of fibrotic
glomeruli probably correlate with the number of damaged
glomeruli. The percentage of glomeruli that are in the process of
disruption and closure need not be high, and I hypothesize that
these glomeruli are responsible for generating the microalbu-
minuria. In addition, segmental changes in individual glomeruli,
that is, localized dilation of glomerular loops, might contribute
to the proteinuria. Thus, the morphologic correlate of microal-
buminuria might be both focal and segmental in nature.
Whether disturbances in charge in the basement membrane play
a role remains to be proven [162, 1631.
Differential diagnosis of microalbuminuria
Before concluding that a diabetic patient has the microalbu-
minuria associated with incipient diabetic nephropathy, other
causes of microalbuminuria must be excluded. Certain transi-
tory and permanent forms are listed in Table 4.
Poor metabolic control of either a profound or long-term
nature in diabetic patients can result in transitory microalbu-
minuria [26, 61, 62, 106—108]. Examples include ketoacidosis
[611 and newly diagnosed diabetes [261. In both instances,
institution of metabolic control readily reverses the microalbu-
minuria. A correlation between UAE and plasma glucose
concentration is not present in patients under conventional
insulin treatment of diabetes with blood glucose levels ranging
from about 50 to 360 mg/dl [701. Some, but not all, studies have
described a weak correlation between UAE and metabolic
control, for example, as measured by glycosylated hemoglobin
[58, 71, 72, 101—1061. Recent observations from our laboratory
have confirmed that acute administration of glucose in diabetic
patients does not increase UAE significantly [401. As I men-
tioned before, protein-rich meals also do not change albumin
excretion [1541.
Moderate physical exercise typically produces a higher level
of UAE in diabetics than in nondiabetics [45—56]. Some evi-
dence suggests that the level of albumin excretion during
exercise is related to the quality of metabolic control; for
example, exercise-induced microalbuminuria is more pro-
nounced in newly diagnosed patients, and this abnormality is
reversed by insulin treatment [54]. Exercise-induced microal-
buminuria generally is not well correlated with the duration of
disease and does not predict clinical nephropathy.
Superimposition of essential hypertension on diabetes can
result in microalbuminuria. However, in non-diabetic patients
with essential hypertension, much higher blood pressure levels
are required to produce levels of microalbuminuria character-
istic of those in patients with incipient diabetic nephropathy [55,
133]. Borderline increases in UAE were found in elderly,
non-insulin-dependent diabetics who had laboratory evidence
of urinary tract infection [881. Finally, non-diabetic renal dis-
ease or systemic diseases, such as congestive heart failure,
should be excluded in evaluating a diabetic patient with micro-
albuminuria. These conditions are rare in young insulin-
dependent patients, however.
In the absence of the conditions I have described, only a few
patients with diabetes and long-term increased urinary albumin
excretion show spontaneous reversal; when it occurs, it is most
often seen in patients whose microalbuminuria falls into the
lower range (UAE less than 30 tg/min) and is associated with a
low blood pressure.
Proposed clinical management and possible influence of
intensified treatment
In my opinion, insulin-dependent diabetic patients require
repeated careful physical and laboratory examination for early
signs of vascular and neurologic complications. At a minimum,
I propose that the physician should measure the UAE with the
patient at rest, perform ophthalmoscopy, determine the blood
pressure, measure the vibration threshold, take a cardiovascu-
lar history, and examine and evaluate the patient's legs. A
thorough evaluation, including measurement of UAE, should
be performed early in the course of the patient's diabetes and
should minimally be repeated every 3 years for the first 9 years
and at yearly intervals thereafter (Table 5). Some diabetologists
may advocate more frequent examination, at least of some of
the parameters. Patients should be informed about the nature of
complications occurring with diabetes during the early exami-
nation, before such complications become apparent. in fact,
patient education should be one of the major reasons for early
examination.
I believe that management for patients with incipient diabetic
nephropathy should encompass the following:
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Examinations
Table 5. Followup in diabetic patients
Measurements for micro- or macroalbuminuria
Eye examination including ophthalmoscopy
Screening for peripheral neuropathy
Vibration threshold examination (on Biothesiometer)
Clinical examination
Resting blood pressure
Clinical history and examinations regarding cardiovascular disease
Foot examination
Multiple measurements of blood glucose and HbA1
Time courses
Without symptoms, signs, or laboratory changes
At admission
Every third year during the first 9 years of diabetes
Blood pressure measurements more often
Annually thereafter
With symptoms, and/or signs, and/or laboratory changes (e.g., high
UAE)
Immediate examination
Time course to be decided in the individual patient (examination
every 3—6 months)
Metabolic control and visit at the clinic every 1—3 months
Some clinicians prefer yearly examination from onset of diabetes
(1) Urinary albumin excretion should be monitored at fre-
quent intervals, about every 3 to 6 months in patients with
elevated UAE, otherwise as I have already indicated. Careful
ophthalmoscopic evaluation is important. Patients should be
informed that an elevated UAE indicates a major risk for the
development of overt diabetic nephropathy. They should be
advised to cooperate in achieving the best possible control of
their diabetes and to adhere to close followup. In my experi-
ence, diabetic patients usually are highly concerned about
long-term complications and take an active part in the treatment
of their disease, including home monitoring of blood glucose,
self monitoring of blood pressure, regular followup, and fre-
quent ophthalmoscopic evaluations. Some authors recommend
a renal biopsy in the evaluation of renal complications [77].
(2) Optimal conventional insulin treatment and self monitor-
ing of blood glucose should be employed to achieve the best
possible control of diabetes. Multiple injection therapy by new
devices such as the "Insulin-Pen" should be considered [164].
Optimal general medical care, including treatment of urinary
tract infection, clearly is important. Evaluation for peripheral
and autonomic neuropathy should be carried out, specifically
with regard to diabetic cystopathy.
A recent randomized study examined the influence of pump
insulin therapy versus conventional insulin treatment on the
microalbuminuria of incipient diabetic nephropathy. No signif-
icant differences between the two regimens could be found after
12 months of followup [661, a finding comparable to that in overt
diabetic nephropathy [165]. Long-term studies over several
years will be required and indeed the 2-year followup of this
study [69] is much more optimistic, since microalbuminuria was
arrested or reversed in the pump group. Progression was seen in
the conventionally treated control patients. Therefore it is likely
that years of poor metabolic control lead to significantly accel-
erated progression in incipient diabetic nephropathy and that
progression can be reversed by good control. Notably, poor
metabolic control, with elevated HbA1 values, has been iden-
tified as a risk factor in overt diabetic nephropathy [166].
In the Kroc study [651, which had an 8-month followup
period, patients with microalbuminuria who were treated with
pump insulin therapy showed a greater tendency toward a
reduction in UAE than did patients treated conventionally [65].
An important criticism of this study, however, is that the
patients were not randomized initially according to careful
estimates of UAE levels; further, a number of patients appeared
to be classified as having microalbuminuria on the basis of a
single initial measurement of UAE [651.
(3) Most authors currently would agree that blood pressure
should be monitored closely in young diabetics at the incipient
stage, and if the level exceeds 140/90—95 mm Hg, antihyperten-
sive treatment should be instituted [59, 111]. Cardioselective
beta blockers and, if needed, diuretics are likely to be effective
[167, 168]. Resting blood pressure should be reduced to less
than 140/90 mm Hg.
Recent longitudinal studies in a small group of patients with
incipient diabetic nephropathy have shown that the progression
of disease, as measured by the yearly change in UAE, can be
reversed by antihypertensive treatment [1111. Six young, male
microalbuminuric patients were followed for a mean of 5 years
prior to treatment and for a mean of 3 years following institution
of antihypertensive therapy with cardioselective beta blockers
and, subsequently, diuretic therapy. Blood pressure was re-
duced by approximately 10% from a baseline of 135/93 mm Hg
to 125/84 mm Hg. The yearly increase in UAE averaged 18%
before treatment and converted to a mean yearly decrease of
21% following institution of therapy. The GFR was supernor-
mal at baseline (mean, 146 mI/mm) and did not change signifi-
cantly during the treatment period [Ill].
These encouraging results require further randomized studies
that include a parallel placebo group. Nonetheless, the results
of this trial are clearly in line with earlier studies on the effect of
antihypertensive treatment in overt diabetic nephropathy [166,
167]. Because the rate of decline in GFR was reduced by 60%,
these studies suggest a delay in the development of uremia in
these patients. It is quite possible that an even greater benefit
might be realized if treatment were initiated earlier, that is, in
patients with incipient diabetic nephropathy or with early overt
nephropathy.
Finally, additional treatment modalities that deserve consid-
eration for vigorous testing in incipient diabetic nephropathy
include low-protein diet regimens, agents that specifically may
reduce intraglomerular pressure (also in stress situations)
[169—172] and, possibly, therapy with thromboxane synthetase
inhibitors [109].
Both patients presented today had microalbuminuria during
their initial presentation. Both patients experienced progression
of their nephropathy. Progression was rapid in the first patient
and occurred during a period of time when metabolic control
was poor. Disease in the second patient progressed at a slower
rate. Both patients improved following institution of antihyper-
tensive treatment.
Conclusion
Studies over the last few years have identified incipient
diabetic nephropathy as a precursor of overt diabetic nephrop-
athy. The incipient stage of the disease is characterized by
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microalbuminuria and, early in the course, a supernormal GFR;
subsequently, GFR tends to decline before clinical proteinuria
supervenes. Blood pressure starts to rise in the incipient stage.
Early renal changes also predict a high risk for subsequent
proliferative retinopathy. Data on insulin pump treatment have
most recently been encouraging; microalbuminuria can be
arrested or reversed with this new form of therapy. New
longitudinal studies show that antihypertensive treatment can
reverse the increase in urinary albumin excretion. Randomized
controlled trials of this and other potential therapeutic modali-
ties deserve consideration.
Questions and answers
DR. MICHAEL W. STEFFES (Department of Laboratory Med-
icine and Pathology, University of Minnesota Medical School,
Minneapolis, Minnesota): Currently there is no clear consensus
on the definition of incipient diabetic nephropathy. This prob-
ably reflects the fact that presently we do not understand the
disease as well as we would like. I would like to ask Dr. Myers
to address the definition of incipient diabetic nephropathy.
DR. BRYAN D. MYERS (Division of Nephrology, Stanford
University School of Medicine, Stanford, California): I think
there is a need to distinguish a transient phenomenon charac-
terized by a functional increase in the albumin excretion rate,
and a much more sinister entity, which is probably the first
stage of overt diabetic glomerulopathy. The notion of functional
microalbuminuria versus incipient diabetic glomerulopathy has
been a real source of confusion to many of us. It seems to me
that there is a consensus that an albumin excretion rate of 200
or 300 gJmin is clearly pathologic and should not be included
in the definition of functional microalbuminuria. Several pieces
of evidence suggest that when albuminuria reaches about 70
gImin, there is a difference in the physiologic behavior of the
kidney. An albumin infusion will predictably increase albumin-
uria when the infusion rate is 70 p.g/min or more. Dr. Viberti has
shown that the selectivity index changes at exactly this level of
microproteinuria, meaning that IgO, a large protein, is now
starting to leak into the urine. I propose that there is now a basis
for considering microalbuminuria as potentially a transient
phenomenon that we can dispel with treatment, and which does
not yet signify an established intrinsic disease of the glomeru-
lus. Perhaps we could agree to set some level of albumin
excretion, probably less than 30 g!min, below which this is
likely to be true. Conversely, we could set a new, lower
boundary for the early stage of diabetic glomerulopathy, say 60
or 70 g/min. Values above this level are likely to signify that
the process is no longer a reversible one.
DR. MOGENSEN: Patients with albumin excretion rates of
more than 70 g/min are clearly at high risk. Also, patients with
albumin excretion at or above that level already show a decline
in GFR. It seems that the decline in GFR starts at an albumin
excretion of about 50 to 70 g/min; therefore, patients excreting
more than 70 gImin are clearly high-risk patients. On the other
hand, patients with UAEs ranging from 20 to 70 g/min also are
clearly at risk, but their risk is not as high as that of patients
with UAEs exceeding 70 g/min; approximately 80% of the
former group (21—70 g/min) will develop nephropathy later,
and it is not surprising that there is a grey area in the lower
range of UAE. We also have to consider that the albumin
excretion rate can, in some instances, be increased by different
mechanisms, for example, in the presence of poor metabolic
control or during physical exercise. Such elevations of albumin
excretion are transient and are much less likely to predict overt
nephropathy. In conclusion, it seems appropriate to deal with
high-risk and low-risk patients, but still I would think that the
range of UAE I have mentioned for incipient diabetic nephrop-
athy is most relevant, namely 20 to 200 g/min in patients
studied in the resting position and not exposed to stress.
DR. GIANCARLO VIBERTI: (Unit for Metabolic Medicine,
Guy's Hospital Medical School, London, England): We have
argued against any definition of incipient diabetic nephropathy
at all, and we have given some reasons for this view [32]. The
situation is somewhat reminiscent to me of what formerly was
called "borderline diabetes," and what is now called "impaired
glucose tolerance." In those days we thought that if one had an
impaired glucose tolerance, one was an "incipient diabetic,"
but this proved an incorrect assumption. Approximately 30% of
patients with impaired glucose tolerance become diabetic, but
an equal proportion regresses to the mean, and their glucose
tolerance returns towards normal. We have to learn much more
than what we already know about the phenomenon of super-
normal albumin excretion rate and its natural evolution. Our
knowledge concerning the progression or regression of this
condition, its quantitative aspects, its relation to blood glucose
control, and its responsiveness to correction of hyperglycemia
is rather limited. I don't think the time is ripe to set new levels
of albumin excretion rate to distinguish between the presence or
absence of disease. We run the risk of repeating the same
mistake we made years ago by setting a level of protein
excretion of 0.5 g/24 hours as a definition of clinical nephrop-
athy. We have discovered now that the disease is in fact part of
a continuum, not a stepwise phenomenon. I support the recom-
mendation of not using any new classification such as persistent
microalbuminuria or incipient nephropathy for the time being,
but simply of limiting ourselves to calling it supernormal levels
of albumin excretion. The significance of this phenomenon will
be much clearer in a few years when natural history studies
have been carried out.
DR. MOGENSEN: There still is a marked difference with regard
to the expected development of subsequent disease in microal-
buminuric patients as compared with patients with glucose
intolerance. In the latter, the risk is rather low, but in patients
with persistently increased albumin excretion rates, the risk is
much higher. I also have said that it might not be necessary to
use any kind of label; if you can use the raw figure, 20, 70, or
100 g/min for an individual patient, you will be able to identify
the approximate level of risk for subsequent overt nephropathy
[1281. Still, it might be very useful to use a label if you are going
to communicate this phenomenon to the general medical com-
munity. Personally, I think it is necessary to have a label, and
that label could be patients "at risk," or those with "persistent
microalbuminuria," "early diabetic nephropathy," or "incipi-
ent diabetic nephropathy." All these labels are appropriate, at
least to my mind.
DR. ELI A. FRIEDMAN (Division of Nephrology, Downstate
Medical Center, Brooklyn, New York): Dr. Mogensen, your
presentation strongly suggests two subpopulations of diabetic
patients who can be distinguished on the basis of albumin
excretion. Furthermore, your data indicate that the subset of
diabetic patients with microalbuminuria is at greater risk of
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developing renal disease and renal insufficiency than is the
group without microalbuminuria. It follows, therefore, that
intensive medical control of diabetes should be directed to
those with microalbuminuria. By contrast, if I understood Dr.
Viberti correctly, he professes that in diabetes there is a
continuum of protein excretion, and that your postulate of two
subpopulations (microalbuminuric and non-microalbuminuric)
might or might not be easily separable. How shall we reconcile
these divergent views? Should we identify the microalbumin-
uric patients because they are to be intensively treated, whereas
patients lacking microalbuminuna can be routinely treated?
DR. MOGENSEN: First, I believe that the albumin excretion
rate in diabetic patients is not a clear-cut continuum in diabetic
populations. Some patients are normal, some clearly abnormal.
In addition, microalbuminuria or increased albumin excretion is
only one abnormality in these patients. As I indicated, these
patients have a number of associated abnormalities. Patients
with persistent microalbuminuna have increases in blood pres-
sure, and in some studies they show glomerular hyperfiltration;
these patients also have increased transcapillary escape of
albumin. All these findings suggest that these patients have
more pronounced vascular abnormalities in general. In addi-
tion, they have more advanced retinopathy. Indeed, patients
with proliferative retinopathy can be identified early using these
methods. You are perfectly right that these patients need
intensive followup and treatment.
DR. STEFFES: Dr. Mogensen, am I correct that you have data
demonstrating a continuum of albuminuria in patients you
followed for several years?
Da. MOGENSEN: Yes, when followed longitudinally, but I
must stress that patients can have completely normal urinary
albumin excretion rates despite a very long duration of diabe-
tes.
DR. VIBERTI: It is important to realize that when we talk
about a continuum in the progression from moderate to severe
elevation of the urinary excretion of albumin, we are referring
to the patients who develop the disease, and not to the 60% who
do not develop the disease. In those who develop the disease,
the available evidence strongly suggests a continuum in the rise
of urinary albumin excretion. Microalbuminuria, or rather,
certain supernormal levels of albumin excretion rate, identify
patients at risk, and these should be the object of more intensive
treatment.
DR. TORSTEN DECKERT (Niels Steensens Hospital, Geniofte,
Denmark): Dr. Mogensen, I think it's important that we recall
your distinction between microalbuminuria on the one hand,
and incipient nephropathy on the other. Whereas microalbu-
minuria is only an expression of the supernormal albumin
excretion, which can be influenced by several factors such as
exercise, blood pressure, and degree of metabolic regulation,
incipient nephropathy means persistent microalbuminuria. I
think we are justified in using the expression "incipient
nephropathy" because several other abnormalities are linked to
this abnormality. Dr. Mogensen has shown that it is linked to a
sinister renal prognosis as well as to progression of retinopathy.
Research has shown that patients with incipient nephropathy as
a group have significantly increased mean blood pressures [71,
83]. We also have shown that these patients have an increased
transcapillary albumin escape rate and decreased plasma albu-
min concentration [173]. Thus, not only are renal abnormalities
connected with this state, but also extrarenal abnormalities. I
therefore think we are justified in having a special expression
for patients with persistent microalbuminuria.
DR. NIcOLA0s E. MADIAS (Chief, Division of Nephrology,
New England Medical Center Hospitals, Boston, Massachu-
setts): Dr. Mogensen, what therapeutic recommendations do
you suggest for patients with microalbuminuria, and what is the
evidence that these maneuvers will alter the course of the
disease?
DR. MOGENSEN: Patients with persistent microalbuminuria
should be offered the best possible conventional treatment or
even pump insulin treatment [69]. As I have indicated, there is
now evidence that treatment with insulin pumps during a 2-year
period can alter the course [69]. We should recognize, however,
that these patients were not too badly controlled before entering
the trial. We also should remember that these patients should
not be subjected to any antihypertensive therapy unless they
have a certain degree of elevated blood pressure. There is no
firm consensus regarding the level, but most authors agree that
a young diabetic patient with persistent microalbuminuria and a
blood pressure of greater than 145/95 mm Hg, or even greater
than 140/90 mm Hg should be given antihypertensive treatment.
DR. MYERS: Is there a consensus among the people here
about a lower level of albumin excretion rate that is likely to be
associated with structural glomerular disease? If, for example,
that level is around 70 pg/mm, could one not make a case for
doing a biopsy and making careful morphometric measure-
ments? If we could confirm a functional-structural association
at the earliest stage of the disease, we could explore ways of
treating the entity at this early stage in the hope of preventing
damage.
Da. FRIEDMAN: Clinicians frequently are compelled to treat
patients on the basis of fragmentary and undigested evidence.
In this regard, when you were characterizing therapeutic ma-
neuvers appropriate to the management of diabetic nephrop-
athy, you omitted three that I would like to hear your specific
comments about. The first is a low-protein diet as advocated by
Giordano for anyone in jeopardy of developing progressive
renal insufficiency [174]. The second is a reduction in blood
pressure below current conventional "normal" levels, perhaps
to 110/70 mm Hg, not just the upper limit of normal. The third
is the lesson taught 40 years ago by Kempner, who advocated
an extremely sodium-restricted rice diet. He was the first
clinician of whom I am aware to show that the clinical expres-
sion of advanced diabetic nephropathy could be arrested, and in
some patients even reversed, by a very low-sodium diet. What
is rational in 1986 as a treatment strategy that must be utilized
before prospective controlled studies are completed, and before
we find out whether microalbuminuria is really predictive? How
do we handle today's patient?
DR. MOGENSEN: I must repeat that whereas microalbumin-
uria is not a perfect predictor, it is an excellent one. What
should we do with the patients? Should we put them on a
low-protein diet? I doubt that we should. There is some
evidence that by doing that you can reduce the GFR from high
values to somewhat lower values, but still we do not know the
long-term effects of such maneuvers, nor do we know whether
patients can adhere to such diets. Future trials are clearly
important. Regarding antihypertensive treatment, we suggest
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that only if the blood pressure exceeds 145/95 or 140/90 mm Hg
should the patient be treated. Regarding a low-sodium rice diet,
it remains an unexplored issue in diabetes. To my knowledge,
there are no firm indications that it alters the course.
DR. OLE ORTvED ANDERSEN (Hillerod Central Hospital,
Dt'n,nark): There is another problem in the definition of "incip-
ient nephropathy." If we arrive at a definition of incipient
nephropathy that means that microalbuminuria is a risk factor,
we must be aware that this may be of significance for the
patients, their employment, insurability, and other factors in
their social life. If you establish such a definition, you must be
sure that the methods for detection are routine.
DR. MOGENSEN: Measurement of the urinary albumin excre-
tion rate in low concentration should be performed in clinical
laboratories. It is a rather easy method.
DR. S. MICHAEL MAUER (Division of Pediatric Nephrology,
University of Minnesota Medical School, Minneapolis, Minne-
sota): I wish to clarify what I hope will not be a confusing point.
When we examined patients with microalbuminuria at a certain
time in their course, we were unable to find any specific
relationship between renal function and structure. However,
progressive structural renal injury is an absolute prerequisite
for the ultimate deterioration of renal function. The question
therefore is clear: Are patients undergoing change in structure
over time that indicates the ultimate loss of renal function? Dr.
Østerby's findings and our findings are converging on this.
Ultimately, in the glomerulus, the filtration surface becomes
altered in a way that leads to deterioration in GFR and
ultimately to uremia. If these lesions don't develop, uremia
doesn't occur. The problem we are trying to focus on is how to
prevent those lesions from developing. But only investigations
into renal structure will yield an answer to our question.
Da. RUTH STERBY (Stereologic and Electron Microscopic
Laboratory for Diabetes Research, University Institute of Pa-
thology, Aarhus, Denmark): I couldn't agree more with what
Dr. Mauer has said. We looked at structural parameters in a
group of diabetic patients with incipient or early nephropathy
characterized by slightly raised urinary albumin excretion and
normal GFR. The severity of glomerular pathology was be-
tween that in patients with short duration of diabetes who have
not yet developed any sign of renal impairment, and that of
patients with overt nephropathy. I think it is clear, as Dr. Mauer
just said, that if these patients do not develop diabetic glomer-
ulopathy, they will not manifest microalbuminuria. There are
two important points to remember in our discussion. First, all of
these diabetic patients with microalbuminuria were earlier
normoalbuminuric; second, we do not yet know whether, by
the time these patients become microalbuminuric, it is too late
to try to prevent the progression to overt nephropathy. We need
more information about what happens structurally before the
functional signs appear.
Da. MAmAS: Is there a particular mode of chronic antihyper-
tensive therapy versus another that makes a difference in terms
of the decrement in the albuminuria? Does an acute decrease in
blood pressure affect albumin excretion?
DR. MOGENSEN: In our long-term study in patients with
incipient diabetic nephropathy, and also in patients with overt
diabetic nephropathy, we used a conventional scheme of treat-
ment. That is, we started with cardioselective beta blockers and
later added, if appropriate, diuretics and, in some cases,
vasodilators. Most patients experienced a satisfactory reduc-
tion in blood pressure with this conventional treatment. Mask-
ing of hypoglycemia was not a problem in our patients when we
used cardioselective beta blockers in moderate doses. Of
course there are other types of antihypertensive treatment, but
all data so far indicate that the method of reducing blood
pressure is not important; rather, it is the degree of reduction in
blood pressure that counts. It might be somewhat different with
ACE inhibitors. In patients with early or with overt diabetic
nephropathy, and also in patients with essential hypertension,
the albumin excretion rate declines markedly after an acute
reduction in blood pressure. After a few hours of reduction in
blood pressure (which may still be moderately elevated), we see
a clear reduction in urinary albumin excretion rate. We there-
fore can conclude that both in early and in overt diabetic
nephropathy the urinary albumin excretion rate is at least partly
pressure dependent. The same is true in patients with essential
hypertension, but in those patients, the blood pressure increase
has to be very pronounced to produce microalbuminuria.
DR. HANS-HENRIK PARVING (HvidOre Hospital, Kiampen-
borg, Denmark): Regarding renal morphology and microalbu-
minuria, we need a morphometric method that predicts the later
development of overt clinical diabetic nephropathy. To my
knowledge we do not have such a method. If we compare renal
biopsies from patients with microalbuminuria with biopsies
from normoalbuminuric patients with the same duration of
diabetes, we cannot tell which of the patients will develop overt
diabetic nephropathy. That issue is the main concern in per-
forming renal biopsies in the "at-risk" patients. Although a
good correlation exists between the GFR and the glomerular
capillary surface area in diabetic nephropathy, the same kind of
morphologic lesions can exist in patients without proteinuna.
Therefore I think we are looking into the wrong window.
Biochemical studies on the composition of the glomerular
basement membrane and charge/size selective properties might
give us a better clue than would structural studies alone.
Da. STEFFES: Are you saying that the functional data are
sufficiently predictive that you don't have to do morphologic
analysis?
DR. PARVING: I think that the best current predictor of
clinical diabetic nephropathy is elevated urinary albumin excre-
tion. The main reason we are not doing a lot of renal biopsies on
our patients in Copenhagen is that do not know what to look
for. I do hope, however, that some investigators will try to
elucidate which morphologic lesions will turn out to be of
predictive or prognostic value.
DR. MAUER: Dr. Parving, I do not agree. All the evidence we
have so far suggests that lesions progress over time, Only renal
transplant recipients have been biopsied serially at 2, 5, 10, and
15 years after the "onset of diabetes." It is clear from these
studies that diabetic nephropathy progresses at a faster rate in
some patients than in others, and that it does not progress at all
in some patients. Returning to the microalbuminuric patients,
when we measure urinary albumin excretion and look at the
structure of the kidney, there is no necessary relationship. I
would argue, however, that if you biopsied the patients who
have microalbuminuria when they had clinical proteinuria, you
would find that they all would have developed significant
lesions. We can agree, based on our current studies, that in
microalbuminuria, a clear structural correlate has not been
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identified, but that somehow it predicts later pathology. It has
to; it can't work any other way. The question is, when you
begin to manipulate that functional finding, are you in fact
influencing the rate of development of pathology? One ap-
proach is to wait until end-stage renal failure develops to
answer this critical question. But this would take a very long
time and it would not allow us to understand mechanisms that
will help us develop better treatment approaches. Further,
studies over an extended period tend to break down because of
noncompliance, patients' geographic dispersal, and other fac-
tors. Twenty-year studies are hard to sustain. Structural mea-
sures could allow us to make our studies manageable.
DR. MOGENSEN: I think it is important to stress the one
situation in which we know that the course can be altered.
Antihypertensive treatment in overt diabetic nephropathy is
associated with a clear reduction in the urinary albumin excre-
tion rate. This observation suggests that in other stages of the
disease, a reduction in the urinary albumin excretion rate is
likely to be beneficial because the rate of decline of the GFR is
also considerably reduced, thus postponing the development of
severe renal failure [167, 168].
DR. PARvING: Dr. Mauer, your points are well taken. How-
ever, this does not solve the problem I put forward. If I gave
you 100 biopsy specimens, you could not tell me which of the
insulin-dependent diabetic patients would or would not develop
clinical diabetic nephropathy. A single biopsy is of little value in
predicting the clinical outcome of renal disease in an individual
patient. It really doesn't matter if the kidneys look bad, as long
as they are functioning. I suggest that longitudinal studies of
urinary albumin excretion rate and GFR are the best methods
for evaluating treatment in microalbuminuric patients, even
though it can take 5 years or more for us to reach a valid
conclusion.
DR. STEFFES: But Dr. Parving, it could take much longer than
5 years for us to reach a conclusion. I think Dr. Mauer's point
is that you might see a morphologic end-point more quickly
than the final functional end-point—renal failure.
DR. PARVING: Longitudinal morphologic studies could turn
out to be a faster method for monitoring the effect of treatment
in incipient diabetic nephropathy. But this method is not
validated. In my opinion, albuminuria and GFR still are the
most crucial variables to be monitored in clinical trials.
DR. MADIAS: Dr. Mogensen, is there any physiologic insight
as to why poor metabolic control or ketosis increases urinary
albumin excretion in the diabetic patient?
DR. MOGENSEN: The pathophysiologic background of the
increase in urinary albumin excretion during poor metabolic
control is not clearly defined, at least not in humans. But much
experimental evidence indicates that the pathophysiologic basis
is an increase in the transcapillary pressure in the glomerulus.
Also, to some extent, decreased tubular reabsorption of pro-
teins plays a role, but probably only a minor one. I must stress
that there are no measurements in humans, but it is well
documented that poor metabolic control in the rat is associated
with an increased transglomerular pressure [158—160].
DR. PARVING: We have some circumstantial evidence in
humans. The filtration fraction is high when a diabetic patient is
in poor metabolic control; reduction of the blood glucose causes
the filtration fraction to fall. These observations suggest that we
are dealing with an elevated glomerular pressure during poor
metabolic control. Furthermore, poor metabolic control is
characterized by increased cardiac output and increased flow to
nearly all organs and tissues: the brain, the eye, muscle,
subcutaneous tissue, and the kidney. Finally, the transcapillary
escape rate of albumin, which is a measurement of the overall
microvascular leakage of albumin, is increased in poorly con-
trolled diabetes and is completely normalized during strict
metabolic control. The findings of normal arterial and venous
pressures and of a reduced vascular resistance, mainly precapil-
lary, suggest that the mean capillary hydrostatic pressure must
be increased in insulin-dependent diabetic patients in poor
metabolic control.
DR. MADrAS: Dr. Mogensen, you have made reference to
exercise-induced microalbuminuria. What sort of exercise are
you talking about? What are the renal hemodynamic effects of
this exercise? What is the meaning of these results?
DR. MOGENSEN: In many patients with standard control of
diabetes, we observed an abnormally high increase in urinary
albumin excretion rate during physical exercise. We also ob-
served a clear reduction in GFR and a more pronounced
reduction in RPF during exercise, that is, an increase in the
filtration fraction. Therefore it is likely that the exercise-
induced microalbuminuria is associated with an increased intra-
glomerular pressure as well. We have studied patients longitu-
dinally, but so far we have no evidence that exercise-induced
microalbuminuria can predict overt diabetic nephropathy or
even baseline microalbuminuria. Yet, as I have indicated, it is
important to eliminate exercise as the cause of microalbu-
minuria because it is a confounding factor; in contrast to
exercise-induced albuminuria, the resting albumin excretion
rate is strongly predictive of overt diabetic nephropathy. There-
fore you should be quite sure that the patients are collecting
urine samples while at rest.
Reprint requests to Dr. C. E. Mogensen, Second University Clinic of
Internal Medicine, Kommunehospitalet, DK-8000 Aarhus C, Denmark
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